Приказ основних података о документу

Koronarni vazodilatatori

dc.creatorStepanović-Petrović, Radica
dc.date.accessioned2019-09-02T11:15:31Z
dc.date.available2019-09-02T11:15:31Z
dc.date.issued2008
dc.identifier.issn0004-1963
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/1152
dc.description.abstractIschemic heart disease is a condition in which there is an inadequate supply of blood and oxygen to a portion of a myocardium. It typically occurs when there is an imbalance between myocardial oxygen supply and demand. The most common cause of myocardial ischemia is atherosclerotic disease of an epicardial coronary artery (or arteries) sufficient to cause a regional reduction in myocardial blood flow and inadequate perfusion of the myocardium supplied by the involved coronary artery. In the treatment of angina pectoris, which is one of the manifestation of ischemic heart disease, among the other drugs used are so cold 'coronary vasodilators' which included organic nitrates and Ca+2 channel antagonists. This paper presents these drugs, by giving the main information about their mechanisms of action, pharmacokinetic characteristics, side effects and interactions with the other drugs.en
dc.description.abstractIshemijska bolest srca je oboljenje kod koga postoji neadekvatno snabdevanje izvesnih delova srca krvlju i kiseonikom. Bolest se manifestuje kada se pojavi nesklad između mogućnosti snabdevanja srca kiseonikom i potreba miokarda za njim. Najčešći uzrok ishemije srca je ateroskleroza epikardijalne koronarne arterije (ili arterija), koja je takva da izaziva regionalnu redukciju protoka krvi kroz srce i neadekvatnu perfuziju tog dela miokarda. U lečenju angine pektoris, koja predstavlja jednu od manifestacija ishemijske bolesti srca, među ostalim lekovima koriste se i tzv. 'koronarni vazodilatatori' u koje se ubrajaju organski nitrati i blokatori kalcijumovih (Ca+2) kanala. Rad prikazuje ove lekove, dajući osnovne informacije o njihovim mehanizmima dejstva, farmakokinetičkim karakteristikama, neželjenim efektima i interakcijama sa drugim lekovima.sr
dc.publisherSavez farmaceutskih udruženja Srbije, Beograd
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-sa/4.0/
dc.sourceArhiv za farmaciju
dc.subjectangina pectorisen
dc.subjectorganic nitratesen
dc.subjecttoleranceen
dc.subjectCa+2channel antagonistsen
dc.subjectangina pektorissr
dc.subjectorganski nitratisr
dc.subjecttolerancijasr
dc.subjectblokatorikalcijumovih (Ca+2) kanalasr
dc.titleCoronary vasodilatorsen
dc.titleKoronarni vazodilatatorisr
dc.typearticle
dc.rights.licenseBY-SA
dcterms.abstractСтепановић-Петровић, Радица; Коронарни вазодилататори; Коронарни вазодилататори;
dc.citation.volume58
dc.citation.issue5-6
dc.citation.spage324
dc.citation.epage333
dc.citation.other58(5-6): 324-333
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/121/1150.pdf
dc.identifier.rcubhttps://hdl.handle.net/21.15107/rcub_farfar_1152
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу